The menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer – Trial protocol of a phase II study

Aims: This study will aim to assess if a composite intervention which involves a specific evidence-based intervention for management of insomnia and non-hormonal pharmacotherapy to manage vasomotor symptoms (VMS) of menopause can improve quality of life for patients experiencing troublesome VMS afte...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fionán Donohoe, Yvonne O'Meara, Aidin Roberts, Louise Comerford, Catherine M. Kelly, Janice M. Walshe, Michelle Peate, Martha Hickey, Donal J. Brennan
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Cancer Menopause symptoms Survivorship Insomnia CBT Quality of life Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/921b7a89bb2646ac8d51b7c7875e52c9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:921b7a89bb2646ac8d51b7c7875e52c9
record_format	dspace
spelling	oai:doaj.org-article:921b7a89bb2646ac8d51b7c7875e52c92021-11-26T04:36:29ZThe menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer – Trial protocol of a phase II study2451-865410.1016/j.conctc.2021.100865https://doaj.org/article/921b7a89bb2646ac8d51b7c7875e52c92021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2451865421001654https://doaj.org/toc/2451-8654Aims: This study will aim to assess if a composite intervention which involves a specific evidence-based intervention for management of insomnia and non-hormonal pharmacotherapy to manage vasomotor symptoms (VMS) of menopause can improve quality of life for patients experiencing troublesome VMS after cancer who are not eligible for standard systemic menopausal hormone therapy (MHT). Participants will be asked to nominate a partner or companion to support them during this process as an additional form of support. Background: The menopause transition and its symptoms represent a significant challenge for many patients after cancer treatment, particularly those for whom conventional MHT is contraindicated. These symptoms include hot flushes, night sweats, urogenital symptoms as well as mood and sleep disturbance. These symptoms can exacerbate the consequences of cancer and its treatment. Methods: We will recruit 205 women who meet inclusion criteria and enrol them on a composite intervention which consists of four parts: (1) use of non-hormonal pharmacotherapy for the management of troublesome vasomotor symptoms of menopause tailored to the timing of predominant symptoms, (2) digital cognitive behavioural therapy for insomnia through the web based Sleepio service, (3) access to information regarding self-management strategies for the common symptoms of menopause and their consequences and (4) identification of a partner or other support person who commits to providing support during the study period. Outcomes: The primary outcome will be cancer specific quality of life measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30). Secondary outcomes will include sleep quality, bother/interference of vasomotor symptoms and communication between couples about their cancer diagnosis and their menopause experience. Sleep will be measured using the Sleep Condition Indicator (SCI) tool, bother/interference of vasomotor symptoms will be measured by the Hot Flush Rating Scale (HFRS) and communication will be measured using the Couples’ Illness Communication Scale (CICS). These validated scales will be administered at baseline, four weeks, three months and six months. Registration: This study is registered on ClinicalTrials.gov with number NCT 04766229.Fionán DonohoeYvonne O'MearaAidin RobertsLouise ComerfordCatherine M. KellyJanice M. WalsheMichelle PeateMartha HickeyDonal J. BrennanElsevierarticleCancerMenopause symptomsSurvivorshipInsomniaCBTQuality of lifeMedicine (General)R5-920ENContemporary Clinical Trials Communications, Vol 24, Iss , Pp 100865- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cancer Menopause symptoms Survivorship Insomnia CBT Quality of life Medicine (General) R5-920
spellingShingle	Cancer Menopause symptoms Survivorship Insomnia CBT Quality of life Medicine (General) R5-920 Fionán Donohoe Yvonne O'Meara Aidin Roberts Louise Comerford Catherine M. Kelly Janice M. Walshe Michelle Peate Martha Hickey Donal J. Brennan The menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer – Trial protocol of a phase II study
description	Aims: This study will aim to assess if a composite intervention which involves a specific evidence-based intervention for management of insomnia and non-hormonal pharmacotherapy to manage vasomotor symptoms (VMS) of menopause can improve quality of life for patients experiencing troublesome VMS after cancer who are not eligible for standard systemic menopausal hormone therapy (MHT). Participants will be asked to nominate a partner or companion to support them during this process as an additional form of support. Background: The menopause transition and its symptoms represent a significant challenge for many patients after cancer treatment, particularly those for whom conventional MHT is contraindicated. These symptoms include hot flushes, night sweats, urogenital symptoms as well as mood and sleep disturbance. These symptoms can exacerbate the consequences of cancer and its treatment. Methods: We will recruit 205 women who meet inclusion criteria and enrol them on a composite intervention which consists of four parts: (1) use of non-hormonal pharmacotherapy for the management of troublesome vasomotor symptoms of menopause tailored to the timing of predominant symptoms, (2) digital cognitive behavioural therapy for insomnia through the web based Sleepio service, (3) access to information regarding self-management strategies for the common symptoms of menopause and their consequences and (4) identification of a partner or other support person who commits to providing support during the study period. Outcomes: The primary outcome will be cancer specific quality of life measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30). Secondary outcomes will include sleep quality, bother/interference of vasomotor symptoms and communication between couples about their cancer diagnosis and their menopause experience. Sleep will be measured using the Sleep Condition Indicator (SCI) tool, bother/interference of vasomotor symptoms will be measured by the Hot Flush Rating Scale (HFRS) and communication will be measured using the Couples’ Illness Communication Scale (CICS). These validated scales will be administered at baseline, four weeks, three months and six months. Registration: This study is registered on ClinicalTrials.gov with number NCT 04766229.
format	article
author	Fionán Donohoe Yvonne O'Meara Aidin Roberts Louise Comerford Catherine M. Kelly Janice M. Walshe Michelle Peate Martha Hickey Donal J. Brennan
author_facet	Fionán Donohoe Yvonne O'Meara Aidin Roberts Louise Comerford Catherine M. Kelly Janice M. Walshe Michelle Peate Martha Hickey Donal J. Brennan
author_sort	Fionán Donohoe
title	The menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer – Trial protocol of a phase II study
title_short	The menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer – Trial protocol of a phase II study
title_full	The menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer – Trial protocol of a phase II study
title_fullStr	The menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer – Trial protocol of a phase II study
title_full_unstemmed	The menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer – Trial protocol of a phase II study
title_sort	menopause after cancer study (macs) - a multimodal technology assisted intervention for the management of menopausal symptoms after cancer – trial protocol of a phase ii study
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/921b7a89bb2646ac8d51b7c7875e52c9
work_keys_str_mv	AT fionandonohoe themenopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT yvonneomeara themenopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT aidinroberts themenopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT louisecomerford themenopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT catherinemkelly themenopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT janicemwalshe themenopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT michellepeate themenopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT marthahickey themenopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT donaljbrennan themenopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT fionandonohoe menopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT yvonneomeara menopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT aidinroberts menopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT louisecomerford menopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT catherinemkelly menopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT janicemwalshe menopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT michellepeate menopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT marthahickey menopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy AT donaljbrennan menopauseaftercancerstudymacsamultimodaltechnologyassistedinterventionforthemanagementofmenopausalsymptomsaftercancertrialprotocolofaphaseiistudy
_version_	1718409854800887808

The menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer – Trial protocol of a phase II study

Ejemplares similares